{"DataElement":{"publicId":"3919905","version":"1","preferredName":"Prior Chemotherapy Somatostatin Analog Therapy Administered Type","preferredDefinition":"Type of prior Somatostatin analog therapy administered.","longName":"SOMATOSTATIN_ANALOGUE","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"3913841","version":"1","preferredName":"Prior Chemotherapy Somatostatin Analog Therapy Administered","preferredDefinition":"Previous chemotherapy administered as treatment for this cancer.:Endocrine drug therapy that uses analogs of somatostatin to treat neuroendocrine tumors._The act of having given something (e.g., a medication or test).","longName":"3654832v1.00:3913839v1.00","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"3654832","version":"1","preferredName":"Prior Chemotherapy","preferredDefinition":"Previous chemotherapy administered as treatment for this cancer.","longName":"C16171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior Chemotherapy","conceptCode":"C16171","definition":"Previous chemotherapy administered as treatment for this cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D40CB30D-C9B2-674C-E040-BB89AD435C4D","latestVersionIndicator":"Yes","beginDate":"2013-01-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2013-01-24","modifiedBy":"ONEDATA","dateModified":"2013-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3913839","version":"1","preferredName":"Somatostatin Analog Therapy Administered","preferredDefinition":"No Value Exists:The act of having given something (e.g., a medication or test).","longName":"C15449:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Somatostatin Analog Therapy","conceptCode":"C15449","definition":"Endocrine drug therapy that uses analogs of somatostatin to treat neuroendocrine tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7D66DB8-6219-D8BA-E040-BB89AD436B36","latestVersionIndicator":"Yes","beginDate":"2013-10-03","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-03","modifiedBy":"ONEDATA","dateModified":"2013-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7D66DB8-622A-D8BA-E040-BB89AD436B36","latestVersionIndicator":"Yes","beginDate":"2013-10-03","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-03","modifiedBy":"KUMMEROA","dateModified":"2023-07-24","changeDescription":null,"administrativeNotes":"2023.7.24 Updated def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3919464","version":"1","preferredName":"Somatostatin Analog Therapy Type","preferredDefinition":"Type of Somatostatin Analog Therapy","longName":"3919464v1.0","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Pasireotide","valueDescription":"Pasireotide","ValueMeaning":{"publicId":"3564437","version":"1","preferredName":"Pasireotide","longName":"3564437","preferredDefinition":"A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhibiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. This agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pasireotide","conceptCode":"C69131","definition":"A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhibiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. This agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7EF39C5-77B3-45DB-E040-BB89AD435B6E","latestVersionIndicator":"Yes","beginDate":"2012-08-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8CA7C7F-FF15-3690-E040-BB89AD43404F","beginDate":"2013-10-15","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-15","modifiedBy":"ONEDATA","dateModified":"2013-10-15","deletedIndicator":"No"},{"value":"Lanreotide","valueDescription":"Lanreotide","ValueMeaning":{"publicId":"3379573","version":"1","preferredName":"Lanreotide","longName":"3379573","preferredDefinition":"A synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lanreotide","conceptCode":"C1523","definition":"A synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-37B4-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8CA7C7F-FF2A-3690-E040-BB89AD43404F","beginDate":"2013-10-15","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-15","modifiedBy":"ONEDATA","dateModified":"2013-10-15","deletedIndicator":"No"},{"value":"Octreotide LAR","valueDescription":"Octreotide Acetate","ValueMeaning":{"publicId":"3919466","version":"1","preferredName":"Octreotide Acetate","longName":"3919466","preferredDefinition":"The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Octreotide Acetate","conceptCode":"C53447","definition":"The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8CA7C7F-FF37-3690-E040-BB89AD43404F","latestVersionIndicator":"Yes","beginDate":"2013-10-15","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8CA7C7F-FF50-3690-E040-BB89AD43404F","beginDate":"2013-10-15","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-15","modifiedBy":"ONEDATA","dateModified":"2013-10-15","deletedIndicator":"No"},{"value":"Octreotide short acting","valueDescription":"Octreotide","ValueMeaning":{"publicId":"3379281","version":"1","preferredName":"Octreotide","longName":"3379281","preferredDefinition":"The synthetic acetate salt of a long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Similar to somatostatin, octreotide suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Octreotide","conceptCode":"C711","definition":"A synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C655-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8CB55D2-F584-CDF9-E040-BB89AD434310","beginDate":"2013-10-15","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-15","modifiedBy":"ONEDATA","dateModified":"2013-10-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3919463","version":"1","preferredName":"Somatostatin Analog Therapy Type","preferredDefinition":"No Value Exists:Something distinguishable as an identifiable class based on common qualities.","longName":"C15449:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Somatostatin Analog Therapy","conceptCode":"C15449","definition":"Endocrine drug therapy that uses analogs of somatostatin to treat neuroendocrine tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8CA7C7F-FEE6-3690-E040-BB89AD43404F","latestVersionIndicator":"Yes","beginDate":"2013-10-15","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-15","modifiedBy":"ONEDATA","dateModified":"2013-10-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8CA7C7F-FEF7-3690-E040-BB89AD43404F","latestVersionIndicator":"Yes","beginDate":"2013-10-15","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-15","modifiedBy":"ROUILLAS","dateModified":"2013-10-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Somatostatin analogue","type":"Preferred Question Text","description":"Somatostatin analogue","url":null,"context":"ECOG-ACRIN"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8CB55D2-F4E3-CDF9-E040-BB89AD434310","latestVersionIndicator":"Yes","beginDate":"2013-10-15","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-15","modifiedBy":"ROUILLAS","dateModified":"2014-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}